Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Pulmatrix stock
Learn how to easily invest in Pulmatrix stock.
Pulmatrix Inc is a biotechnology business based in the US. Pulmatrix shares (PULM) are listed on the NASDAQ and all prices are listed in US Dollars. Pulmatrix employs 20 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Pulmatrix
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – PULM – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Pulmatrix stock price (NASDAQ: PULM)Use our graph to track the performance of PULM stocks over time.
Pulmatrix shares at a glance
|Latest market close||$0.40|
|52-week range||$0.39 - $3.04|
|50-day moving average||$0.59|
|200-day moving average||$0.82|
|Wall St. target price||$5.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.39|
Buy Pulmatrix shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Pulmatrix stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Pulmatrix price performance over time
|1 week (2022-01-08)||N/A|
|1 month (2021-12-17)||-16.00%|
|3 months (2021-10-19)||-45.33%|
|6 months (2021-07-19)||-55.17%|
|1 year (2021-01-19)||-70.44%|
|2 years (2020-01-17)||-75.52%|
|3 years (2019-01-18)||63.12%|
|5 years (2017-01-19)||0.9201|
|Revenue TTM||$6.7 million|
|Gross profit TTM||$-2,975,000|
|Return on assets TTM||-19.28%|
|Return on equity TTM||-55.43%|
|Market capitalisation||$22.4 million|
TTM: trailing 12 months
Pulmatrix share dividends
We're not expecting Pulmatrix to pay a dividend over the next 12 months.
Have Pulmatrix's shares ever split?
Pulmatrix's shares were split on a 1:10 basis on 5 February 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Pulmatrix shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Pulmatrix shares which in turn could have impacted Pulmatrix's share price.
Pulmatrix share price volatility
Over the last 12 months, Pulmatrix's shares have ranged in value from as little as $0.385 up to $3.04. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pulmatrix's is 1.1921. This would suggest that Pulmatrix's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Pulmatrix, Inc. , a clinical stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug that is in Phase 2b clinical trials for the prevention and treatment of fungal infections and allergic/hypersensitivity reactions to fungus in patients with severe lung diseases comprising asthma, cystic fibrosis, and allergic bronchopulmonary aspergillosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with lung cancer and chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc.
Pulmatrix in the news
Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
Frequently asked questionsWhat percentage of Pulmatrix is owned by insiders or institutions?
Currently 0.003% of Pulmatrix shares are held by insiders and 30.285% by institutions. How many people work for Pulmatrix?
Latest data suggests 20 work at Pulmatrix. When does the fiscal year end for Pulmatrix?
Pulmatrix's fiscal year ends in December. Where is Pulmatrix based?
Pulmatrix's address is: 99 Hayden Avenue, Lexington, MA, United States, 02421 What is Pulmatrix's ISIN number?
Pulmatrix's international securities identification number is: US74584P2020 What is Pulmatrix's CUSIP number?
Pulmatrix's Committee on Uniform Securities Identification Procedures number is: 74584P103
More guides on Finder
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
How to buy Specialty Building Products (SBP) stock when it goes public
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Ask an Expert